RNA Insider Notice: 95,052 Shares to Be Sold via UBS on Nasdaq

Rhea-AI Filing Summary

Form 144 filed for Avidity Biosciences (RNA) reports a proposed sale of common stock totaling 95,052 shares with an aggregate market value of $4,752,600, to be sold through UBS Financial Services on Nasdaq on 09/05/2025. The filing lists the issuer's total shares outstanding as 128,653,337, so the proposed sale represents a small fraction of the company’s outstanding stock.

The filer shows prior acquisitions including a stock option exercise on 09/05/2025 for 14,500 shares paid in cash and long-held shares acquired in 2018 and 2012 totaling 80,552 shares. The filing also discloses multiple related-party sales on 08/06/2025 totaling 97,054 shares with combined gross proceeds reported.

Positive

• Transparency: The filing discloses the planned brokered sale, prior acquisitions, and recent related-party sales, meeting Rule 144 disclosure requirements
• Scale: Proposed sale (95,052 shares, $4.75M) is a very small portion (~0.074%) of 128,653,337 outstanding shares, suggesting limited market impact

Negative

• Insider selling: Multiple sellers and recent sales on 08/06/2025 totaling 97,054 shares were disclosed, which some investors may view as a negative signal despite small scale

Insights

Securities Analyst

TL;DR: Insider-related selling disclosed; the size is small relative to float and appears routine rather than a material corporate event.

The filing notifies the market of a planned brokered sale of 95,052 common shares valued at $4.75 million via UBS on 09/05/2025. With 128.65 million shares outstanding, this sale represents roughly 0.074% of outstanding shares, indicating limited dilution or market impact. The schedule shows prior intrafamily and trust sales on 08/06/2025 and recent option exercise, which may reflect portfolio rebalancing or liquidity events rather than new information about company fundamentals. No earnings, regulatory, or operational disclosures are included in this filing.

Corporate Governance Expert

TL;DR: Disclosure complies with Rule 144 reporting; multiple related trust sales and an exercise are disclosed, but no adverse governance signals are evident from this notice alone.

The document provides required Rule 144 notice of proposed sale and documents the provenance of shares (long-held shares and recent option exercise). The presence of sales by trusts and family members is noted; such transfers are common in estate planning and do not by themselves indicate governance issues. The filer affirms no undisclosed material adverse information. Absent other filings or contextual disclosures, this notice is a routine insider disclosure.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc Eleven Madison Avenue 4th floor New York NY 10010	95052	4752600.00	128653337	09/05/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/05/2025	Stock Option exercise	Issuer			14500	09/05/2025	Cash
Common	04/18/2018	Long shares	Issuer			15000	04/18/2018	NA
Common	11/17/2012	Long shares	Issuer			65552	11/17/2012	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Troy Wilson 3020 CALLAN ROAD SAN DIEGO CA 92121	Common	08/06/2025	29500	1327500.00
The Wacky Wednesday Irrevocable Trust DTD 11/1/2023 3020 CALLAN ROAD SAN DIEGO CA 92121	Common	08/06/2025	15000	675000.00
The Mulberry Street Irrevocable Trust DTD 11/1/2023 3020 CALLAN ROAD SAN DIEGO CA 92121	Common	08/06/2025	15000	675000.00
2012 Oh the Places You'll Go! Irrevocable Trust FBO Isabella Hsieh Wilson DTD 7/29/2012 3020 CALLAN ROAD SAN DIEGO CA 92121	Common	08/06/2025	17777	799965.00
2012 Oh the Places You'll Go! Irrevocable Trust FBO Zoe Hsieh Wilson DTD 7/29/2012 3020 CALLAN ROAD SAN DIEGO CA 92121	Common	08/06/2025	17777	799965.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Avidity Biosciences (RNA) disclose?

It discloses a proposed sale of 95,052 common shares valued at $4,752,600 through UBS on 09/05/2025 and lists prior related sales on 08/06/2025.

How large is the proposed sale versus Avidity's outstanding shares?

The company has 128,653,337 shares outstanding, so the proposed sale equals approximately 0.074% of outstanding shares.

Were the shares to be sold recently acquired?

Some shares were acquired via a stock option exercise on 09/05/2025 (14,500 shares paid in cash) and other lots were long-held from 2018 and 2012.

Did the filing report prior sales by related parties?

Yes; related individuals and trusts reported sales on 08/06/2025 totaling 97,054 shares with combined gross proceeds reported.

Does this Form 144 indicate undisclosed material information about the company?

The filer represents they do not know of any undisclosed material adverse information; the filing itself contains no operational or financial disclosures indicating such information.